Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
163.46B
Market cap163.46B
Price-Earnings ratio
10.61
Price-Earnings ratio10.61
Dividend yield
3.33%
Dividend yield3.33%
Average volume
18.44M
Average volume18.44M
High today
$36.98
High today$36.98
Low today
$35.63
Low today$35.63
Open price
$36.00
Open price$36.00
Volume
14.70M
Volume14.70M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Nasdaq 1d
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight

Key Points Foundayo (orforglipron) has a serious advantage over Novo Nordisk's Wegovy pill. Retatrutide, a subcutaneous triple hormone receptor agonist in pha...

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
TipRanks 2d
Omeros Turns Corner With Novo Deal, YARTEMLEA Launch

Omeros Corporation ((OMER)) has held its Q4 earnings call. Read on for the main highlights of the call. End of Quarter Sale - 50% Off TipRanks Unlock hedge fund...

The Motley Fool 2d
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market

Over the past two years, Novo Nordisk (NVO +1.23%) has lost its lead in the anti-obesity space to its biggest competitor, Eli Lilly (LLY 1.98%). The Denmark-bas...

Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market

Analyst ratings

61%

of 36 ratings
Buy
30.6%
Hold
61.1%
Sell
8.3%

More NVO News

Simply Wall St 3d
Novo Nordisk Wegovy Subscription Targets Self Pay Demand And Investor Focus

Novo Nordisk (NYSE:NVO) has launched a multi month subscription program for its obesity drug Wegovy. The program targets self pay patients, aiming to provide m...

Novo Nordisk Wegovy Subscription Targets Self Pay Demand And Investor Focus
TipRanks 4d
Wegovy vs. Foundayo: Novo Nordisk’s “Record-Breaking” Run Meets the Eli Lilly Challenge

Shares in Danish drugmaking giant Novo Nordisk (NVO) — already down about 26% since the start of the year — are now facing even more pressure after American arc...

Nasdaq 4d
Novo Nordisk's Wegovy Approved For Cardiovascular Event Risk Reduction In England

(RTTNews) - Novo Nordisk [NVO] announced on Wednesday, that it has received a significant boost after the National Institute for Health and Care Excellence reco...

Novo Nordisk's Wegovy Approved For Cardiovascular Event Risk Reduction In England
TipRanks 4d
Novo Nordisk in focus as FDA approves Eli Lilly’s Foundayo

Shares of Novo Nordisk (NVO) are in focus at midday after the Food and Drug Administration approved Eli Lilly’s (LLY) GLP-1 pill. Eli Lilly announced on Wednesd...

Simply Wall St 5d
Did Hims & Hers' Novo Nordisk GLP-1 Partnership Just Shift Hims & Hers Health's Investment Narrative?

In March 2026, Hims & Hers Health announced a collaboration with Novo Nordisk to offer eligible customers a broad range of FDA-approved GLP-1 medications, inclu...

Did Hims & Hers' Novo Nordisk GLP-1 Partnership Just Shift Hims & Hers Health's Investment Narrative?
TipRanks 5d
Omeros reports Q4 EPS $1.22, consensus 36c

Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth quarter also includes a $136.0 mil...

Cheddar 5d
Novo Nordisk Launches Wegovy Subscription Plans to Lower Costs and Boost Patient Retention

Novo Nordisk Launches Wegovy Subscription Plans to Lower Costs and Boost Patient Retention Novo Nordisk is introducing multi-month subscription plans for its W...

Novo Nordisk Launches Wegovy Subscription Plans to Lower Costs and Boost Patient Retention

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.